Nuclear GSK3β promotes tumorigenesis by phosphorylating KDM1A and inducing its deubiquitylation by USP22

Nature Cell Biology

Volumn 18, Issue 9, 2016, Pages 954-966

  Zhou, Aidong ^a   Lin, Kangyu ^a   Zhang, Sicong ^a,b   Chen, Yaohui ^a   Zhang, Nu ^c   Xue, Jianfei ^a   Wang, Zhongyong ^a   Aldape, Kenneth D ^a,e   Xie, Keping ^a,b   Woodgett, James R ^d   Huang, Suyun ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c SUN YAT SEN UNIVERSITY   (China)

^d MOUNT SINAI HOSPITAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; CASEIN KINASE IALPHA; CELL PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; GLYCOGEN SYNTHASE KINASE 3BETA; HISTONE DEMETHYLASE; HISTONE H3; KDM1A PROTEIN; LYSINE; NUCLEAR PROTEIN; SERINE; TEMOZOLOMIDE; TIDEGLUSIB; TRANSCRIPTION FACTOR GATA 6; UNCLASSIFIED DRUG; USP22 PROTEIN; 4 BENZYL 2 METHYL 1,2,4 THIAZOLIDINE 3,5 DIONE; AOF2 PROTEIN, MOUSE; GSK3B PROTEIN, HUMAN; GSK3B PROTEIN, MOUSE; HISTONE; KDM1A PROTEIN, HUMAN; PROTEINASE; THIADIAZOLE DERIVATIVE; THIOL ESTER HYDROLASE; USP22 PROTEIN, HUMAN; USP22 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BMP2 GENE; CANCER COMBINATION CHEMOTHERAPY; CANCER STEM CELL; CANCER SURVIVAL; CANCER TISSUE; CARCINOGENESIS; CDKN1A GENE; CELL SELF-RENEWAL; CHEMOSENSITIZATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INDUCTION; ENZYME LOCALIZATION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; ENZYME STABILITY; GATA6 GENE; GENETIC TRANSCRIPTION; GLIOBLASTOMA; HISTONE METHYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; TUMOR XENOGRAFT; UBIQUITINATION; ANIMAL; CELL PROLIFERATION; DRUG EFFECTS; METABOLISM; NUDE MOUSE; PHOSPHORYLATION; TUMOR CELL LINE;

ANIMALS; CARCINOGENESIS; CELL LINE, TUMOR; CELL PROLIFERATION; ENDOPEPTIDASES; GLIOBLASTOMA; GLYCOGEN SYNTHASE KINASE 3 BETA; HISTONE DEMETHYLASES; HISTONES; HUMANS; MICE, NUDE; PHOSPHORYLATION; THIADIAZOLES; THIOLESTER HYDROLASES; UBIQUITINATION;

EID: 84981234065     PISSN: 14657392     EISSN: 14764679     Source Type: Journal    
DOI: 10.1038/ncb3396     Document Type: Article

References (54)

1. Cohen, P., & Frame, S. The renaissance of GSK3. Nat. Rev. Mol. Cell Biol. 2, 769-776 (2001
2. Doble, B. W., & Woodgett, J. R. GSK-3: tricks of the trade for a multi-Tasking kinase. J. Cell Sci. 116, 1175-1186 (2003
3. Hoeflich, K. P., et al. Requirement for glycogen synthase kinase-3α in cell survival and NF-kappa;B activation. Nature 406, 86-90 (2000
4. Farago, M., et al. Kinase-inactive glycogen synthase kinase 3α promotes Wnt signaling and mammary tumorigenesis. Cancer Res. 65, 5792-5801 (2005
5. Wang, Z., et al. GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis. Cancer Cell 17, 597-608 (2010
6. Naito, S., et al. Glycogen synthase kinase-3-: a prognostic marker and a potential therapeutic target in human bladder cancer. Clin. Cancer Res. 16, 5124-5132 (2010
7. Aberle, H., Bauer, A., Stappert, J., Kispert, A., & Kemler, R.β-catenin is a target for the ubiquitin-proteasome pathway. EMBO J. 16, 3797-3804 (1997
8. Sears, R., et al. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 14, 2501-2514 (2000
9. Tang, Q. L., et al. Glycogen synthase kinase-3-, NF-kappa;B signaling, and tumorigenesis of human osteosarcoma. J. Natl Cancer Inst. 104, 749-763 (2012
10. Miyashita, K., et al. Potential therapeutic effect of glycogen synthase kinase 3α inhibition against human glioblastoma. Clin. Cancer Res. 15, 887-897 (2009
11. Ougolkov, A. V., et al. Aberrant nuclear accumulation of glycogen synthase kinase-3α in human pancreatic cancer: association with kinase activity and tumor dedifferentiation. Clin. Cancer Res. 12, 5074-5081 (2006
12. Ougolkov, A. V., Bone, N. D., Fernandez-Zapico, M. E., Kay, N. E., & Billadeau, D. D. Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factorκB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells. Blood 110, 735-742 (2007
13. Reddiconto, G., et al. Targeting of GSK3α promotes imatinib-mediated apoptosis in quiescent CD34C chronic myeloid leukemia progenitors, preserving normal stem cells. Blood 119, 2335-2345 (2012
14. Esteller, M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet. 8, 286-298 (2007
15. Hill, E. V., et al. Glycogen synthase kinase-3 controls IL-10 expression in CD4(C) effector T-cell subsets through epigenetic modification of the IL-10 promoter. Eur. J. Immunol. 45, 1103-1115 (2015
16. Shi, Y. J., et al. Regulation of LSD1 histone demethylase activity by its associated factors. Mol. Cell 19, 857-864 (2005
17. Wang, Y., et al. LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell 138, 660-672 (2009
18. Lv, S., et al. LSD1 is required for chromosome segregation during mitosis. Eur. J. Cell Biol. 89, 557-563 (2010
19. Kauffman, E. C., et al. Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer. Mol. Carcinog. 50, 931-944 (2011
20. Hayami, S., et al. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int. J. Cancer 128, 574-586 (2011
21. Harris, W. J., et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell 21, 473-487 (2012
22. Sareddy, G. R., et al. KDM1 is a novel therapeutic target for the treatment of gliomas. Oncotarget 4, 18-28 (2013
23. Suva, M. L., et al. Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells. Cell 157, 580-594 (2014
24. Gong, A. H., et al. FoxM1 drives a feed-forward STAT3-Activation signaling loop that promotes the self-renewal and tumorigenicity of glioblastoma stem-like cells. Cancer Res. 75, 2337-2348 (2015
25. Rena, G., Bain, J., Elliott, M., & Cohen, P. D4476, a cell-permeant inhibitor of CK1, suppresses the site-specific phosphorylation and nuclear exclusion of FOXO1a. EMBO Rep. 5, 60-65 (2004
26. Adamo, A., et al. LSD1 regulates the balance between self-renewal and differentiation in human embryonic stem cells. Nat. Cell Biol. 13, 652-659 (2011
27. Sun, G., et al. Histone demethylase LSD1 regulates neural stem cell proliferation. Mol. Cell. Biol. 30, 1997-2005 (2010
28. Dominguez, J. M., et al. Evidence for irreversible inhibition of glycogen synthase kinase-3α by tideglusib. J. Biol. Chem. 287, 893-904 (2012
29. Bolos, M., Fernandez, S., & Torres-Aleman, I. Oral administration of a GSK3 inhibitor increases brain insulin-like growth factor I levels. J. Biol. Chem. 285, 17693-17700 (2010
30. Sereno, L., et al. A novel GSK-3α inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo. Neurobiol. Dis. 35, 359-367 (2009
31. Chen, J., et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488, 522-526 (2012
32. Liu, C., et al. Control ofβ-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 108, 837-847 (2002
33. Gregory, M. A., Qi, Y., & Hann, S. R. Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization. J. Biol. Chem. 278, 51606-51612 (2003
34. Shin, S., Wolgamott, L., Yu, Y., Blenis, J., & Yoon, S. O. Glycogen synthase kinase (GSK)-3 promotes p70 ribosomal protein S6 kinase (p70S6K) activity and cell proliferation. Proc. Natl Acad. Sci. USA 108, E1204-E1213 (2011
35. Kotliarova, S., et al. Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappa;B, and glucose regulation. Cancer Res. 68, 6643-6651 (2008
36. Beurel, E., & Jope, R. S. Differential regulation of STAT family members by glycogen synthase kinase-3. J. Biol. Chem. 283, 21934-21944 (2008
37. Park, B. H., Qiang, L., & Farmer, S. R. Phosphorylation of C/EBPα at a consensus extracellular signal-regulated kinase/glycogen synthase kinase 3 site is required for the induction of adiponectin gene expression during the differentiation of mouse fibroblasts into adipocytes. Mol. Cell. Biol. 24, 8671-8680 (2004
38. Foltz, D. R., Santiago, M. C., Berechid, B. E., & Nye, J. S. Glycogen synthase kinase-3α modulates notch signaling and stability. Curr. Biol. 12, 1006-1011 (2002
39. Kubic, J. D., Mascarenhas, J. B., Iizuka, T., Wolfgeher, D., & Lang, D. GSK-3 promotes cell survival, growth, and PAX3 levels in human melanoma cells. Mol. Cancer Res. 10, 1065-1076 (2012
40. Schaeffer, V., et al. Binding of OTULIN to the PUB domain of HOIP controls NF-kappa;B signaling. Mol. Cell 54, 349-361 (2014
41. Elliott, P. R., et al. Molecular basis and regulation of OTULIN-LUBAC interaction. Mol. Cell 54, 335-348 (2014
42. Wu, Y., et al. The deubiquitinase USP28 stabilizes LSD1 and confers stem-cell-like traits to breast cancer cells. Cell Rep. 5, 224-236 (2013
43. Zhang, X. Y., et al. The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression. Mol. Cell 29, 102-111 (2008
44. Lin, Z., et al. USP22 antagonizes p53 transcriptional activation by deubiquitinating Sirt1 to suppress cell apoptosis and is required for mouse embryonic development. Mol. Cell 46, 484-494 (2012
45. Tolosa, E., et al. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov. Disord. 29, 470-478 (2014
46. Persano, L., et al. BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1α stability and MGMT expression. Cell Death Differ. 3, e412 (2012
47. Kamnasaran, D., Qian, B., Hawkins, C., Stanford, W. L., & Guha, A. GATA6 is an astrocytoma tumor suppressor gene identified by gene trapping of mouse glioma model. Proc. Natl Acad. Sci. USA 104, 8053-8058 (2007
48. Ligon, K. L., et al. Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. Neuron 53, 503-517 (2007
49. Hirose, Y., Berger, M. S., & Pieper, R. O. p53 effects both the duration of G2/M arrest and the fate of temozolomide-Treated human glioblastoma cells. Cancer Res. 61, 1957-1963 (2001
50. Schonberg, D. L., et al. Preferential iron trafficking characterizes glioblastoma stemlike cells. Cancer Cell 28, 441-455 (2015
51. Hu, Y., & Smyth, G. K. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J. Immunol. Methods 347, 70-78 (2009
52. Zhang, N., et al. FoxM1 promotesβ-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis. Cancer Cell 20, 427-442 (2011
53. Shembade, N., & Harhaj, E. W. Elucidating dynamic protein-protein interactions and ubiquitination in NF-kappa;B signaling pathways. Methods Mol. Biol. 1280, 283-295 (2015
54. Li, M., et al. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 416, 648-653 (2002